Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology

Eldi, Preethi; Cooper, Thomas J.; Liu, Liang; Prow, Natalie A.; Diener, Kerrilyn R.; Howley, Paul M.; Suhrbier, Andreas; Hayball, John D.

doi:10.1016/j.ymthe.2017.06.017

Cited by 18 publications

(70 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SCV technology was used to develop a vaccine against chikungunya virus (CHIKV), with the SCV chikungunya vaccine (SCV-CHIK) encoding the structural gene cassette of CHIKV. A single vaccination with SCV-CHIK provided protection against CHIKV infection and arthritic diseases in a wild-type (C57BL/6) adult mouse model 2 , which recapitulates many aspects of human CHIKV disease 3 , 4 . CHIKV is a mosquito-borne alphavirus that is primarily associated with acute and chronic rheumatic symptoms, with occasional infections also resulting in severe disease manifestations and mortality 5 , 6 .…”

Section: Introductionmentioning

confidence: 88%

“…For instance, a Modified Vaccinia Ankara (MVA) smallpox vaccine, IMVAMUNE® 1 , was recently approved in the European Union and Canada. We recently described the Sementis Copenhagen Vector (SCV) vaccine technology and its application to vaccine development 2 . The SCV platform was generated by deleting the D13L gene from the Copenhagen strain of VACV.…”

Section: Introductionmentioning

confidence: 99%

“…The SCV platform was generated by deleting the D13L gene from the Copenhagen strain of VACV. D13L encodes an essential viral assembly protein (D13) and its deletion renders SCV incapable of generating viral progeny in vaccine recipients 2 . This approach to attenuation preserves genome amplification, thereby permitting late phase expression of vaccine antigens from the amplified vector genomes 2 .…”

Section: Introductionmentioning

confidence: 99%

“…D13L encodes an essential viral assembly protein (D13) and its deletion renders SCV incapable of generating viral progeny in vaccine recipients 2 . This approach to attenuation preserves genome amplification, thereby permitting late phase expression of vaccine antigens from the amplified vector genomes 2 . The second unique feature of the SCV vaccines is that it can be produced in a SCV cell substrate (SCS) cell line, which comprises Chinese hamster ovary (CHO) cells stably expressing D13 and CP77.…”

Section: Introductionmentioning

confidence: 99%

“…The second unique feature of the SCV vaccines is that it can be produced in a SCV cell substrate (SCS) cell line, which comprises Chinese hamster ovary (CHO) cells stably expressing D13 and CP77. In trans provision of D13 allows SCV assembly and the host-range protein, CP77, imparts VACV and SCV multiplication capability to SCS cells 2 . CHO cells are widely used in the biopharmaceutical industry, with SCV vaccine production in the SCS cell line avoiding many of the issues associated with vaccine manufacture in primary chicken embryo fibroblasts, the cells traditionally used for production of vaccinia-based vaccines 2 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses

et al. 2018

Self Cite

View full text Add to dashboard Cite

Zika and chikungunya viruses have caused major epidemics and are transmitted by Aedes aegypti and/or Aedes albopictus mosquitoes. The “Sementis Copenhagen Vector” (SCV) system is a recently developed vaccinia-based, multiplication-defective, vaccine vector technology that allows manufacture in modified CHO cells. Herein we describe a single-vector construct SCV vaccine that encodes the structural polyprotein cassettes of both Zika and chikungunya viruses from different loci. A single vaccination of mice induces neutralizing antibodies to both viruses in wild-type and IFNAR−/− mice and protects against (i) chikungunya virus viremia and arthritis in wild-type mice, (ii) Zika virus viremia and fetal/placental infection in female IFNAR−/− mice, and (iii) Zika virus viremia and testes infection and pathology in male IFNAR−/− mice. To our knowledge this represents the first single-vector construct, multi-pathogen vaccine encoding large polyproteins, and offers both simplified manufacturing and formulation, and reduced “shot burden” for these often co-circulating arboviruses.

show abstract

Section: Introductionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Current view on novel vaccine technologies to combat human infectious diseases

Matić

Šantak

2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1-3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. Key points• Vaccines of the new generation follow the minimalist strategy.• Some infectious diseases remain a challenge for the vaccine development.• The number of new vaccine candidates in the late phase clinical trials remains low.

show abstract